Katie focuses her practice on drafting and prosecuting US and foreign patent applications for clients in the biotechnology and pharmaceutical industries.  She also conducts due diligence, prepares freedom to operate analyses, and provides litigation support.

Katie has experience drafting and prosecuting patents in the areas of CRISPR/Cas gene editing, immunotherapy, microbiome, recombinant protein therapy, iPS cells/MSCs, small molecule therapeutics, antibodies/immune checkpoint inhibitors, and molecular diagnostics.   

Prior to joining Mintz, Katie’s postdoctoral and graduate work involved the expression, purification, and enzymatic characterization of the Alzheimer’s Disease target protein, BACE1; structure-based drug design for the identification and development of novel potent inhibitors; kinetic characterization of inhibitors using steady-state kinetic assays; and extensive synchrotron experience for automated X-ray crystallographic data collection.

Earlier in her career, Katie was a production scientist in the immunodiagnostics division of an international biomedical testing company and worked at a large food company as a research scientist.